Based on the science behind a new diagnostic test, diarrhea-predominant irritable bowel syndrome appears to be an autoimmune process in at least some patients, new research has found. When a biomarker for antibodies to an endogenous protein in the gut is added to a biomarker for small intestinal bacterial overgrowth (SIBO), the positive predictive value of the test climbs above 95%.
The test, which is being marketed by Gemelli Biotech, builds on the already convincing evidence that SIBO